

Scaling up to meet global demand





The COVID-19 pandemic demands that we move with unprecedented urgency, which is why we've been rapidly building our capacity to produce our investigational oral antiviral COVID-19 medicine.

Standing up the largest manufacturing capacity in under 12 months in our company's history

We manufactured 10 million courses of treatment by the end of 2021, with at least 20 million additional courses expected to be produced in 2022.


Investing at risk to meet the urgent health need

Our manufacturing teams started to produce our investigational oral antiviral COVID-19 medicine at scale in late 2020, before we had substantial clinical data.



May 2020

MSD announces agreement with Ridgeback Biotherapeutics to develop a novel, oral antiviral candidate



July 2020

MSD begins producing clinical supplies and initiates plans for scale up

December 2020

MSD achieves production of 25,000 courses of treatment

November 2021

First doses shipped to the UK

January 2022

Doses shipped to over 25 countries

Working around the globe


We are utilizing our global network, including manufacturing sites in 9 countries across 3 continents.

- USA
- Puerto Rico
- Canada
- Netherlands
- Italy
- China
- Japan
- Ireland
- India

Our supply chain is comprised of 17 internal and external plants globally. We use a diverse network of internal and external suppliers, packaging plants and distributors.

Working with generic manufacturers

We recognize the role that generic medicines can play in meeting the needs of many people in the developing world. As evidenced by our voluntary licensing agreements with established Indian generics manufacturers and with the Medicines Patent Pool, we are committed to expanding access to medicines globally, including through the availability of high-quality generics in developing countries.



The pandemic continues to be an unrivaled global health challenge. We are moving with urgency and rigor to bring our investigational oral antiviral COVID-19 medicine to patients as quickly as we can.

